mammary cells

[Cell Reports] Fibrotic-like matrix stiffness promoted distinct metastatic phenotypes in breast cancer cells, which were preserved after transition to softer microenvironments, such as bone marrow.

[Scientific Reports] A patient-derived scaffold model was evaluated as a testing platform for the endocrine therapies (Z)-4-Hydroxytamoxifen and fulvestrant as well as the CDK4/6-inhibitor palbociclib, monitoring the treatment responses in breast cancer cell lines MCF7 and T47D adapted to the patient-based microenvironments.

[Communications Biology] Scientists indicated that CSCs may enjoy blood perfusion to maintain their stemness features. Targeting the lysophosphatidic acid/protein kinase D -CD36 signaling pathway may have therapeutic potential to curb tumor progression by disrupting the arteriolar niche and effectively eliminating CSCs.

[Science Signaling] Researchers identified delayed down-regulated genes (DDGs) in mammary cells after prolonged treatment with epidermal growth factor (EGF). The expression of these DDGs was low in mammary tumors and correlated with prognosis.

[Signal Transduction and Targeted Therapy] Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4.

[Cancer Research] Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, researchers reported an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer.